Cardiology – Myocardial Necrosis Markers
CK-MB mass (creatine kinase isoenzyme MB)
CK-MB mass is a creatine kinase (CK) isoenzyme specifically assayed in blood by immunoassay to quantify the fraction of CK of myocardial origin. Total creatine kinase is a ubiquitous enzyme catalyzing the transfer of a phosphate group from phosphocreatine to ADP to regenerate ATP in tissues with high energy demand - mainly skeletal muscle, myocardium and brain. It exists in three dimeric isoforms depending on the combination of its two M and B subunits: CK-MM (dominant in skeletal muscle), CK-BB (dominant in brain and smooth tissue) and CK-MB, present in the myocardium at a proportionally higher concentration than in any other tissue (8 to 25 % of total CK in myocardium, versus 1 to 3 % in skeletal muscle). It was this relative cardiac specificity of the MB fraction that made CK-MB the reference biomarker for the diagnosis of acute myocardial infarction (AMI) for several decades, from its clinical description in the 1970s to the late 1990s. It has since been progressively supplanted by cardiac troponin - in particular ultra-sensitive troponin - whose cardiac specificity is absolute, early sensitivity superior and ability to detect microscopic myocardial necrosis incomparably better. Mass CK-MB nevertheless retains clinical indications complementary to troponin, notably for the detection of early reinfarction after a first event (its faster normalization kinetics than troponin enable a new peak to be distinguished from a residual plateau), assessment of infarct size, and post-interventional monitoring after cardiac surgery or coronary angioplasty. A distinction should be made between CK-MB mass - a quantitative immunological protein assay in µg/L or ng/mL, the only one recommended - and CK-MB activity, a less specific and less sensitive enzymatic assay that is gradually being abandoned in modern laboratories.
Biochemistry and Physiology of CK-MB
Understanding the biochemistry of CK-MB illuminates its clinical utility and limitations:
- Total creatine kinase (CK) is a dimeric enzyme whose total activity in the blood is mainly of skeletal muscle origin; its elevation is non-specific (trauma, intramuscular injections, intense exercise, myopathies, hypothyroidism) and of little diagnostic value for myocardial infarction taken in isolation.
- CK-MB represents 8 to 25 %of total CK in the myocardium; it is also present in small amounts in skeletal muscle (1 to 3 % ), the small intestine, the uterus, the prostate, and the tongue — which explains its potential false positives in severe skeletal muscle trauma, inflammatory myopathies, and extreme physical exercise.
- During myocardial necrosis, CK-MB is released into the myocardial interstitium, drained into the coronary lymphatics and venous circulation, and becomes detectable in the blood approximately 3 to 6 hours after the onset of ischemia; its plasma peak is reached at 12 to 24 hours, and levels return to normal within 48 to 72 hours — a shorter kinetic profile than that of troponin I or T (which remain elevated for 7 to 14 days).
- Immunological mass assay (in µg/L) is the recommended method, as it directly measures the concentration of CK-MB protein independently of its enzyme activity; it is more sensitive and specific than the enzymatic method (CK-MB activity in U/L), particularly because it is not affected by the presence of macroenzymes or atypical isoforms.
- The CK-MB/total CK ratio (isoenzyme ratio) is a complementary tool: a ratio greater than 5-6 % suggests a cardiac origin even if absolute values are in a tricky interpretation range, allowing differentiation between an increase of cardiac origin and an increase of purely skeletal muscle origin.
Reference values
The normal values for CK-MB mass vary slightly depending on the methods and analyzers used by laboratories; the values below correspond to the most commonly used thresholds in Canada:
| Population | Normal value (CK-MB mass) | Interpretation |
|---|---|---|
| Adult (male and female) | < 5.0 µg/L (ng/mL) | Normal limits; does not exclude very early MI (< 3 to 4 hours after symptom onset) or very small MI; must be interpreted with kinetics (serial measurements) and clinical context |
| Diagnosis threshold for MI | > 5.0 µg/L with a dynamic increase ≥ 1.5 to 2 times over two consecutive assays at 3 to 6 hour intervals | Dynamic elevation suggestive of myocardial necrosis; must be interpreted in conjunction with clinical presentation, ECG, and troponin. |
| Picture during an extended IDM | Often 50 to 200 µg/L, sometimes over 500 µg/L for very extensive MI | The peak CK-MB level is approximately correlated with the size of myocardial necrosis and the residual left ventricular ejection fraction; it is used in research to quantify infarct size. |
| Post-cardiac surgery (coronary artery bypass graft) | Expected elevation up to 3 to 5 times the upper limit of normal without pathological significance. | An elevation of CK-MB greater than 5 to 10 times the upper limit of normal within 72 hours after coronary artery bypass grafting is defined as a peri-procedural MI according to ESC/ACC criteria (universal definition of MI). |
| Percutaneous Coronary Intervention (PCI) | Moderate elevation possible after interventional procedure without MI | An elevation of CK-MB above 3 times the upper limit of normal after elective PCI is defined as a periprocedural MI according to current criteria |
Comparative kinetics of CK-MB, troponin, and myoglobin
Each cardiac marker has a specific kinetics of elevation and normalization that determines its optimal diagnostic window:
| Marker | Time to appear in blood | Plasma picnic | Back to normal | Primary Clinical Utility |
|---|---|---|---|---|
| Myoglobin | 1 to 3 hours | 6 to 9 AM | 12 to 24 hours | Earliest marker; very sensitive but not specific (abundant skeletal muscle); high negative predictive value at 6 hours to exclude MI; abandoned in most modern protocols in favor of troponin us |
| CK-MB mass | 3 to 6 hours | 12 to 24 hours | 48 to 72 hours | Detection of early re-infarction (new peak after normalization); assessment of infarct size; diagnosis of peri-procedural MI (PCI, bypass); complement to troponin in certain algorithms |
| Troponin I or T (classical method) | 4 to 8 hours | 12 to 24 hours (cTnI) / 12 to 48 hours (cTnT) | 7 to 10 days (cTnI) / 10 to 14 days (cTnT) | Reference marker for MI diagnosis since the 2000s; absolute cardiac specificity; sensitivity superior to CK-MB for small necroses |
| High-sensitivity cardiac troponin (hs-cTn) | 1 to 3 hours | 12 to 24 hours | 7 to 14 days | Current standard for MI diagnosis; allows for 0/1-hour or 0/2-hour rule-out algorithms in the emergency department; detects microscopic necroses invisible to other markers; serial measurements at 0 and 1 hour (or 0 and 3 hours) are sufficient in most modern protocols |
ℹ️
The rapid normalization of CK-MB within 48 to 72 hours, unlike troponin which remains elevated for 7 to 14 days, represents its main residual clinical advantage in the era of ultrasensitive troponin. In a patient admitted for a myocardial infarction that occurred several days prior (troponin still elevated at baseline), CK-MB will allow for more precise dating of the event. Furthermore, in a patient with a documented prior myocardial infarction presenting with new chest pain, an increase in CK-MB above the normal value (while troponin remains elevated at baseline from the first event) is highly suggestive of reinfarction.
Current clinic indications for CK-MB mass
Although high-sensitivity troponin has become the marker of choice for diagnosing MI, mass CK-MB still has specific clinical indications:
- Detection of early reinfarctions occurring within 72 hours of a first MI, a period during which troponin remains elevated at a residual plateau, making it impossible to distinguish between residual elevation and new necrosis; CK-MB, which normalizes within 48 to 72 hours after the first event, will allow the detection of a new peak if a second infarction occurs.
- Infarct size assessment and residual ejection fraction estimation: the area under the CK-MB curve (area defined by serial measurements) is correlated with the necrotic myocardial mass; used in clinical research and in certain post-MI prognostic assessment protocols.
- Diagnosis and quantification of peri-procedural MI after PCI or CABG, where moderate troponin elevations are expected and CK-MB allows for more precise quantification of procedure-related necrosis according to Universal Definition of Myocardial Infarction criteria
- Monitoring the effectiveness of thrombolysis or coronary reperfusion: an early peak in CK-MB (rapid washout of the isoenzyme during reperfusion) before the 12th hour is an indirect marker of successful coronary reperfusion, although angiography remains the gold standard.
- Troponin supplementation in centers without access to ultrasensitive troponin or in diagnostic algorithms integrating both markers to improve overall sensitivity and specificity
- Non-cardiac post-surgical context: CK-MB can be measured after major surgery to distinguish skeletal muscle-derived elevations in total CK (expected and non-specific) from perioperative myocardial injury, although troponin remains preferable in this setting.
Causes of elevated CK-MB
CK-MB is not exclusively a cardiac marker, and several non-cardiac situations can elevate its absolute value, hence the importance of the CK-MB/total CK ratio and kinetics for interpretation.
| Cause | Origin | Features and Distinction with IDM |
|---|---|---|
| Acute myocardial infarction | Cardiac | Dynamic elevation (increase ≥ 50 % on serial assays at 3 to 6 hours), peak at 12 to 24 hours, normalization in 48 to 72 hours; CK-MB/total CK ratio > 5 to 6 %; parallel elevation of troponin; compatible clinical and ECG context |
| Acute myocarditis | Cardiac | Often moderate and prolonged elevation, without as sharp a peak and descent profile as with IDM; young patient context, viral context, diffuse atypical chest pain; cardiac MRI for confirmation |
| Electrical cardioversion (defibrillation) | Cardiac / iatrogenic | Transient microscopic myocardial necrosis caused by external electrical shock; moderate and brief elevation of CK-MB; troponin slightly elevated depending on energy delivered |
| Severe chest trauma (myocardial contusion) | Traumatic cardiac | Myocardial contusion after blunt chest trauma (traffic accident, fall); ECG often abnormal (ectopic beats, bundle branch block); elevated CK-MB and troponin; echocardiography to assess ventricular function |
| Severe inflammatory myopathy (polymyositis, dermatomyositis) | Skeletal muscle | Skeletal muscle necrosis containing 1–3 % of CK-MB can raise absolute CK-MB proportionally to very high total CK; CK-MB/total CK ratio generally < 5 %; no elevation of troponin in the absence of associated cardiac involvement |
| Severe rhabdomyolysis (traumatic, drug-induced, toxic) | Skeletal muscle | Very high total CK (often > 10,000 to 100,000 U/L) with proportionally increased CK-MB but ratio < 5 %; characteristic myoglobinuria (brown-red urine); possible acute renal failure; absence of electrocardiographic evidence of MI |
| Cardiac surgery (coronary artery bypass grafting, valve replacement) | Iatrogenic heart | Expected elevation proportional to the duration of surgery and aortic clamping time; a disproportionate elevation (> 5 to 10 times the ULN) indicates perioperative myocardial infarction. |
| Extreme physical exercise (marathon, triathlon) | Skeletal muscular / possible cardiac component | Transient elevation of CK-MB after intense and prolonged exertion; ratio generally within normal limits; ultrasensitive troponin may also rise transiently after extreme exertion with no pathological significance in elite athletes |
CK-MB versus high-sensitivity troponin: a clinical comparison
High-sensitivity troponin has largely supplanted CK-MB as the preferred biomarker for diagnosing MI in current guidelines. Understanding their differences helps determine when CK-MB remains relevant:
| Criteria | CK-MB mass | High-sensitivity cardiac troponin (hs-cTn) |
|---|---|---|
| Cardiac specificity | Relative (also present in skeletal muscle, the intestine, the uterus) | Absolute for the myocardium (cTnI and cTnT are found only in negligible amounts outside the myocardium) |
| Sensitivity for small necroses | Limited — does not detect micro-infarcts or lesions of less than 1 g of myocardium | Very high—detects necroses of a few mg of myocardium; elevation in virtually 100 % of angiographically confirmed MI |
| Onset time | 3 to 6 hours after the onset of ischemia | 1 to 3 hours for ultra-sensitive methods |
| Rise time | 48 to 72 hours (rapid normalization) | 7 to 14 days (long diagnostic window) |
| Usefulness for early reinfarction | Excellent—rapid normalization allows detection of a new peak | Difficult if the second MI occurs within 7 to 14 days (troponin still elevated from the first event) |
| Current recommendations | Additional marker; not recommended as first-line for MI diagnosis according to ESC 2020 | First-line marker according to all international recommendations (ESC, ACC/AHA); 0/1h or 0/2h algorithms validated in the emergency department |
| Non-cardiac causes of elevation | Numerous (skeletal muscle, rhabdomyolysis, myopathies) | Fewer but real (chronic kidney failure, chronic heart failure, pulmonary embolism, severe sepsis, stroke) |
ℹ️
The isolated measurement of CK-MB mass at a single point in time does not allow for the distinction between an MI and an elevation of non-cardiac origin. It is the dynamics of change over serial measurements—an increase of 50 % or more between two measurements 3 to 6 hours apart, in concordance with the troponin curve—that constitutes the diagnostic criterion for active myocardial necrosis. A persistently high value without significant increase over time is more indicative of a chronic non-ischemic cause (heart failure, myopathy) than an active MI.
Practical procedure for the sample collection
CK-MB mass measurement is most often part of a serial cardiac marker evaluation in an emergency setting:
- Standard venous blood draw on serum tube (red or yellow cap) or EDTA tube (purple cap) according to laboratory requirements; no fasting required
- In the context of an emergency for suspected acute coronary syndrome (ACS), an initial CK-MB measurement is taken upon admission (T0), then repeated at 3 hours or 6 hours depending on the local protocol to assess the rise dynamics; this serial measurement is concurrent with serial ultra-sensitive troponin measurements.
- Inform the prescribing physician of any recent intramuscular injection, strenuous physical activity within the last 48 hours, recent surgery, or muscle trauma, which may elevate total CK and incidentally CK-MB without cardiac significance.
- The result is generally available in 30 to 60 minutes in emergency (STAT) laboratories equipped with the appropriate automated analyzers.
- The CK-MB/Total CK ratio should be calculated and mentioned in the report to help distinguish between a cardiac and skeletal muscle origin; a ratio greater than 5 to 6 % indicates the myocardium, while a lower ratio indicates skeletal muscle.
Signs requiring immediate emergency care
Any recent chest pain—especially constrictive or crushing pain radiating to the left arm, jaw, or back, accompanied by sweating, nausea, or shortness of breath—is a medical emergency that requires calling 911 immediately or going to the emergency room without delay. CK-MB and troponin levels will be measured in the emergency room as part of the workup for suspected acute coronary syndrome. Do not wait for biological abnormalities to appear before consulting: a normal ECG and initially normal markers do not rule out an early MI, hence the importance of serial measurements taken over several hours.
For the interpretation of an abnormal CK-MB or troponin result discovered during a routine check-up, or to evaluate cardiac symptoms outside of an immediate emergency context, Clinique Omicron offers structured medical consultations at its service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron supports patients in interpreting cardiac markers, assessing cardiovascular risk, and directing them to appropriate cardiology resources at its service points in Quebec and via telemedicine. A physician or a nurse practitioner (NP) can interpret your CK-MB and troponin results within their clinical context, perform an ECG, prescribe necessary further investigations, and coordinate a referral to a cardiologist or an emergency department if the situation requires it. To book an appointment, visit cliniqueomicron.ca.
The content on this page is for informational purposes only and does not substitute for advice from a qualified healthcare professional. Any acute chest pain constitutes a medical emergency; call 911 or go to the emergency room immediately.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.